The aim of the study was to selectively deliver BG to the glioblastoma in mice, inhibit the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT), and overcome Temozolomide resistance. This evidence concerns the gene MGMT and glioblastoma.